IL17A and benign prostatic hyperplasia: Despite of the 5α-Reductase inhibitors, few new medications was found in the market and very few targets of BPH have been confirmed at present, although some markers as oxytocin (Xu H. et al., 2017; Li et al., 2018) IL-17 and ANGPT2 (Arivazhagan et al., 2017) involved in BPH development are in research recently.